Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma

Abroad (travel likely)Recruiting

Conditions

Nasopharyngeal Carcinoma · Sintilimab

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China
Contact: Study coordinator (Ling Li, MD) · lilingmoon99@163.com · 8615977737210

Study leads

Xiao-Dong Zhu, Doctor
Principal Investigator
Cancer Hospital of Guangxi Medical University
Ling Li, Master
Principal Investigator
Cancer Hospital of Guangxi Medical University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC

Nasopharyngeal Carcinoma (NPC)

Abroad (travel likely)RecruitingPHASE3

Nanning, China

Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Abroad (travel likely)RecruitingPHASE3

Guangzhou, China

Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"

Malignant Head and Neck Neoplasm · Malignant Neoplasm · Metastatic Malignant Neoplasm in the Neck

Abroad (travel likely)Recruiting

Houston, United States

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

Sinonasal Neuroendocrine Carcinoma · Nasopharyngeal Carcinoma · Esthesioneuroblastoma

Abroad (travel likely)RecruitingPHASE1

Bethesda, United States